Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps.
Chronic rhinosinusitis with nasal polyps
Eosinophilic
Mepolizumab
Smell sense loss
Journal
Clinical and molecular allergy : CMA
ISSN: 1476-7961
Titre abrégé: Clin Mol Allergy
Pays: England
ID NLM: 101152195
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
11
2018
accepted:
05
02
2019
entrez:
27
2
2019
pubmed:
26
2
2019
medline:
26
2
2019
Statut:
epublish
Résumé
Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab. The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting. In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction of the nasal obstruction by nasal polyps.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a significant impairment in quality of life. The medical treatments currently available may improve the olfactory function in patients with CRSwNP, but such an outcome is generally only transitory. We report the case of a patient with CRSwNP who completely recovered from smell sense loss by treatment with mepolizumab.
CASE PRESENTATION
METHODS
The patient was a 62-year-old female who has severe asthma induced by allergy to Dermatophagoides and concomitant CRSwNP. Any treatment for the latter, including oral and injective corticosteroids, was unsuccessful in the loss of smell. Due to the satisfaction of admission criteria to mepolizumab treatment for severe asthma, treatment was initiated on March 2018, resulting in good clinical control of both asthma and CRSwNP, and particularly in complete recovery of the smell loss after 4 months of treatment and still persisting.
CONCLUSION
CONCLUSIONS
In this case report, the treatment with mepolizumab in a patient allergic to Dermatophagoides and affected by CRSwNP was associated with an improvement of anosmia. That finding may be explained by a reduction of the nasal obstruction by nasal polyps.
Identifiants
pubmed: 30804712
doi: 10.1186/s12948-019-0106-2
pii: 106
pmc: PMC6373033
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3Références
Rhinology. 2012 Mar;50(1):1-12
pubmed: 22469599
J Asthma. 2018 Feb;55(2):152-160
pubmed: 28622052
J Allergy Clin Immunol. 2017 Oct;140(4):1024-1031.e14
pubmed: 28687232
Ann Otol Rhinol Laryngol. 2017 Nov;126(11):739-747
pubmed: 28918644
J Biol Regul Homeost Agents. 2018 Jan-Feb;32(1):167-169
pubmed: 29504383
Rhinol Suppl. 2017 Mar;54(26):1-30
pubmed: 29528615
Curr Allergy Asthma Rep. 2018 Jul 11;18(9):46
pubmed: 29995271
Eur Arch Otorhinolaryngol. 2018 Sep;275(9):2193-2202
pubmed: 30027441